MDP Regulatory Insight

Lessons from FDA’s Breast Binder Warning Letters

In December 2025, the FDA issued warning letters to several companies selling breast binders and chest compression garments online.

The agency concluded that marketing claims on company websites, like statements about compressing breast tissue, relieving gender dysphoria, or supporting post-surgical recovery, positioned the products as medical devices under the Federal Food, Drug, and Cosmetic Act.

And because the firms had not registered their establishments or listed the products with FDA, the agency cited them for misbranding.

Product Marketing May Determine Its Regulatory Status

The episode illustrates a core regulatory principle: a product’s regulatory status is often determined by how it is marketed, not by how it looks.

Compression garments may appear to be ordinary apparel, but when claims suggest they treat a condition or affect the body’s structure or function, FDA may classify them as medical devices.

FDA May Face Legal Challenges

A recent legal analysis from industry attorneys at Hyman, Phelps & McNamara suggests the FDA may face challenges over the enforcement approach to breast binders. They note that the warning letters cite only a technical violation (failure to register and list) even though therapeutic binders would normally fall into the lowest-risk device category (Class I, 510(k)-exempt) which does not require establishment registration and product listings on the FDA website.

They also point out that under FDA’s own Regulatory Procedures Manual, warning letters are typically reserved for violations of “regulatory significance,” while registration and listing issues are often resolved through less formal communications.

In short, the attorneys argue that the enforcement action appears driven less by the technical violation and more by the marketing context surrounding gender dysphoria claims.

For manufacturers and retailers, the practical lesson is straightforward. Clothing can become a medical device if it is promoted as solving a health-related problem.

A Strategic Marketing Decision

Companies selling compression garments or similar products must make a strategic decision to market them strictly as apparel with non-medical claims or accept device status and comply with FDA registration and device listing requirements.

Either path can work, but drifting between the two can invite regulatory scrutiny.

Bottom Line

The warning letters appear to reflect a coordinated enforcement sweep, likely driven by systematic reviews of publicly available website claims. When multiple companies use similar language, particularly around conditions such as gender dysphoria, FDA can quickly identify patterns and apply the same regulatory logic across many sellers at once.

The broader lesson is that regulatory status is often a function of messaging. FDA doesn’t need a product to “look medical” to treat it as a device. A company’s marketing claims can do that for them. For companies selling compression garments or similar products, the key decision is strategic. Either remain clearly in the consumer apparel space by avoiding medical or condition-based claims or accept device status and comply with the associated regulatory requirements.